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TO THE EDITOR
Malignant melanoma is one of the least
chemosensitive human cancers. The
cause of drug resistance in melanoma
remains poorly understood. So far, no
cytotoxic regimen has revealed superio-
rity compared to dacarbazine mono-
therapy (Eggermont and Kirkwood, 2004).
Although mutations inactivating the
TP53 gene (encoding the p53 protein)
are rare events in melanoma (Hartmann
et al., 1996), p53 may be inactivated
through other mechanisms. The murine
double-minute oncogene (MDM2) binds
to and ubiquitinates p53 (Piette et al.,
1997), and MDM2 amplification has
been found responsible for p53 inactiva-
tion in some malignancies (Momand
et al., 1998). Recently, an MDM2
promoter polymorphism (SNP309T4G)
increasing MDM2 expression through
enhanced binding of the Sp1 transcrip-
tional activator was shown to enhance
carcinogenesis (Bond et al., 2004).
p14ARF activates p53 by inhibiting
MDM2 binding (Figure 1a); thus, loss of
p14ARF may reduce p53 function
(Efeyan and Serrano, 2007). Although
p14ARF in general is activated in
response to oncogenic stimulation, there
is evidence that p14ARF may also be
involved in response to genotoxic stress
(Christophorou et al., 2006). p14ARF is
encoded by ‘‘the alternative reading
frame’’ of the CDKN2A gene. Although
most CDKN2A mutations identified in
melanoma affect the p16INK4a tran-
script only (Grafstrom et al., 2005;
Knappskog et al., 2006; Goldstein
et al., 2007), mutations affecting the 50
half of exon 2 may affect both transcripts.
Here, we analyzed pretreatment
tumor biopsies from 85 patients
receiving dacarbazine for advanced
malignant melanoma (Busch et al.,
unpublished data) for potential distur-
bances in p53, MDM2, p14ARF, or
p16INK4a. Pretreatment biopsies from
all patients were snap frozen in liquid
nitrogen. Each patient provided written
informed consent, and the study
protocol was approved by the regional
ethical committee. The study was
conducted according to the Declaration
of Helsinki Principles. Of the 85 pati-
ents, 75 were evaluable for clinical
response according to the UICC-criteria
(Busch et al., unpublished data). RNA
was extracted with TRIzol (Invitrogen,
Carlsbad, CA), and cDNA was synthe-
sized with reverse transcriptase (Roche
Diagnostics, Basel, Switzerland). The
tumors were screened for TP53 and
CDKN2a mutations andMDM2 promo-
ter status by PCR amplification and
subsequent sequencing. In addition,
intragenetic deletions or amplifications
in CDKN2A or MDM2 were screened
for using MLPA (MRC Holland,
Amsterdam, the Netherlands; Schouten
et al., 2002). mRNA expression
analysis of p16INK4a and BMI-1 was
performed in a duplex qRT-PCR system
(LightCycler 480; Roche Diagnostics)
using TaqMan probes and b-2-micro-
globulin as an internal reference.
Dilutions of PCR products of these
genes were included in each run to
make a standard curve for calculation
of relative concentrations.
We considered the ‘‘p53 pathway’’
to be disturbed in tumors harboring
one of the following events: TP53 or
p14ARF mutations causing amino-acid
changes, biallelic p14ARF deletions,
MDM2 amplification, and/or homozyg-
osity for the SNP309G haplotype.
To evaluate the impact of p16INK4a
expression levels, we compared tumors
expressing p16INK4a above or below
median of the analyzed samples.
Potential correlations between
molecular parameters and clinical
outcome were tested using the Fisher’s
exact test comparing objective respon-
ders (complete response or partial
response) to nonresponders (progressive
disease or stable disease) or stable
disease þ complete response/partial
response versus progressive disease.
Univariate analyses were performed
analyzing different factors impact on
time to progression and overall survival
(OS) using log-rank test. Variables
with P-value o0.10 were entered into
Abbreviations: BMI-1, polycomb ring finger oncogene; MDM2, mouse double-minute homolog;
OS, overall survival
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a Cox regression model (multivariate).
In addition, Breslow thickness of the
primary tumor and serum lactate
dehydrogenase levels (Bosserhoff, 2006;
Balch et al., 2009) were included in the
multivariate model.
Out of 79 patients successfully seq-
uenced for TP53, three harbored
polymorphisms (G108A/P36P in 2 and
A639/R213R in 1 patient). One tumor
harbored a somatic mutation leading to
an amino acid change (T402A/F134L),
whereas two tumors harbored large
deletions (exons 2–9 and exons 4–10),
removing most of the coding region.
For MDM2, 3 out of 83 evaluable
tumors harbored copy number changes.
One tumor revealed a single allele
deletion, whereas two tumors con-
tained gene amplification. MDM2
SNP309 analyses revealed 37 patients
(44%) to harbor the TT genotype, 35
(41%) had the TG genotype, and 13
(15%) were of the GG genotype.
Although we identified four (4.7%)
single-nucleotide mutations in the
p16INK4a transcript of CDKN2A, three
of these mutations affected the 30 end of
exon 2 specific for the p16INK4a
transcript, whereas one affected both
p16INK4a and p14ARF. CDKN2A
heterozygote deletions were identified
in 7 patients (8.4%), and homozygous
deletions in 18 patients (22%).
Hypermethylation of the p14ARF
promoter was found in two patients
(2.4%) only. In contrast, the p16INK4a
promoter was hypermethylated in
19 tumors (22%, Table 1a).
No correlation between tumor re-
sponse and either individual gene or
combined gene alterations in the p53
pathway was recorded.
In univariate analyses, no single gene
alteration or combinations of genes
significantly predicted time to progres-
sion. Age at metastasis, gender, or
Breslow thickness were not associated
with time to progression, whereas lac-
tate dehydrogenase strongly predicted
time to progression (P¼ 0.007).
Alteration in the p53 pathway, how-
ever, predicted OS (P¼0.003). In addi-
tion, we found OS positively correlated to
p16INK4a expression level (P¼0.037).
Breslow thickness and lactate dehydro-
genase strongly predicted OS (P¼ 0.027
and Po0.001, respectively), whereas age
or gender were not associated with OS.
Surprisingly, we detected a positive
correlation between expression of
p16INK4a and BMI-1, considered to be
its main suppressor (Jacobs et al., 1999),
Pearson’s R¼ 0.584, Po0.001. BMI-1
expression did not predict OS.
Combining alterations in the p53
pathway (þ /) and p16INK4a expres-
sion levels (above/below median)
strongly predicted OS when comparing
all groups together (P¼0.006, Figure 1b).
The difference was particular striking
when comparing patients with tumors
expressing high p16INK4a levels and
normal p53 status to patients with
tumors expressing low p16INK4a levels
and p53 disturbances (P¼ 0.003).
Complete listing of different multi-
variate models is given in Table 1b.
Alterations in the p53 pathway and
p16INK4a expression level proved
to be prognostic factors of OS
independent of serum lactate dehydro-
genase, but only alterations in the p53
pathway were independent of Breslow
thickness.
In conclusion, we found distur-
bances in the p53/MDM2/p14ARF axis
as well as p16INK4a expression levels
to be of prognostic value with respect to
OS. In contrast, our results provided
no evidence favoring disturbances in
this pathway to be a major factor
Damaged DNA
ATM ATM
p53
a
b
Chk2
P
Pp53
Cell-cycle
arrest
Low p16 and p53 pathway alterations
Low p16 and no p53 pathway alterations
High p16 and p53 pathway alterations
High p16 and no p53 pathway alterations
Censored
O
ve
ra
ll 
su
rv
iva
l
1.0
0.8
0.6
0.4
0.2
0.0
0 20 40 60 80 100
P =0.006
Metastasis to death (months)
Apoptosis DNA repair
M
D
M
2
M
D
M
2
p14ARF
Oncogene activation Cell stress
ATR
Casein
Kinase II
Figure 1. Schematic presentation of the p53 pathway and effects of p53 alterations and/or p16
expression level on patient survival. (a) Mouse double-minute homolog (MDM2) binds to and
ubiquitinates p53. p14ARF binds to MDM2 and thereby prevents MDM2 binding p53, thus stabilizing
p53. (b) Kaplan–Meier plot with the time parameter overall survival where the patients are classified
into four groups based on p16INK4a expression (above vs. below median) and whether or not
they harbored any major disturbance in the p53 pathway.
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predicting response to dacarbazine
monotherapy.
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Table 1a. Overview of genetic alterations in TP53, MDM2, and p14ARF
Gene Type of alteration n Frequency (%) Specification
TP53 Mutations (single mutations) 3/79 3.8 T402A/F134L
del 193-37(UTR)
del -26-993
MDM2 Amplification 2/83 2.4
Deletion 1/83 1.2
SNP 37/85 44 309 T/T
SNP 35/85 41 309 G/T
SNP 13/85 15 309 G/G
CDKN2a Biallelic deletion 18/83 22
Uniallelic deletion 7/83 8.0
p14ARF Promoter hypermethylation 2/85 2.4
Mutations (single mutations) 1/85 1.1 G305T/G102V
p16INK4a Promoter hypermethylation 19/85 22
Mutations (single mutations) 4/85 4.7 C341T/P114L
C341T/P114L
G379T/A127S
G262T/E88Ter
Abbreviation: SNP, single-nucleotide polymorphism.
Table 1b. Multivariate analyses on overall survival showing variables
entered and results for three different models
Model number Variable entered1 P-value, HR (95% confidence interval)
1 s-LDH2 P=0.016, HR=0.52 (0.29–0.88)
p53 status P=0.045, HR=0.57 (0.32–0.99)
2 s-LDH Po0.001, HR=0.34 (0.20–0.58)
p16INK4a expression P=0.024, HR=1.8 (1.1–3.0)
3 s-LDH P=0.009, HR=0.45 (0.25–0.82)
p16INK4a expression P=0.10, HR=1.6 (0.91–2.8)
p53 status P=0.18, HR=0.66 (0.36–1.21)
Abbreviations: HR, hazard ratio; s-LHD, serum lactate dehydrogenase.
1Adding Breslow thickness to the different models, p53 status remained a significant predictor in
model 1, but not in 3. p16INK4a expression was lost as a significant predictor in model 2, whereas
Breslow thickness and s-LDH remained significant in all three models.
2s-LDH was entered into each model as a marker of tumor burden.
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